On May 28, 2024 NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, reported abstract acceptance at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2024 Annual Meeting being held May 31- June 4, 2024, at the McCormick Place, Chicago, IL (Press release, NeoTX, MAY 28, 2024, View Source;utm_medium=rss&utm_campaign=neotx-announces-poster-presentation-at-asco-2024-annual-meeting [SID1234643740]). The poster will present preliminary results of clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in a phase 2 trial in patients with advanced/ metastatic non-small cell lung cancer (NSCLC) which have been pretreated with standard chemotherapy and a checkpoint inhibitor (CPI). Details on the presentation are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract Title:
Clinical Activity and Safety of Naptumomab Estafenatox (NAP) and Docetaxel in Patients (pts) with Checkpoint Inhibitor (CPI) Pre-treated Advanced/ Metastatic Non-Small Cell Lung Cancer (NSCLC) – Preliminary Results, P2 Trial
Abstract Number:
8615
Session Type and Title:
Poster Session – Lung Cancer—Non-Small Cell Metastatic
Session Date & Time:
Monday June 3, 2024, 1:30 PM – 4:30 PM CDT